All In Biotech

Drug Trial Radar · NCT05171855

A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

A Multicenter, Open-Label, Extension Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

Last checked: Nov 20, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

220

Actual

Start

Dec 16, 2021

Primary completion

Dec 23, 2024

Study completion Dec 23, 2024

Sponsor

Sponsor type
Industry
First posted
Dec 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 23 years, up to 81 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a phase 3 open-label multicenter extension study designed to evaluate the long-term safety and efficacy of Lonapegsomatropin administered once-weekly. The study participants were adults (males and females) with confirmed growth hormone deficiency (GHD) having completed the treatment period in study TCH-306 (foresiGHt; NCT04615273).

Conditions

  • Adult Growth Hormone Deficiency
  • Endocrine System Diseases
  • Hormone Deficiency

Interventions

  • LonapegsomatropinDrug

    Study participants were individually dosed with subcutaneous injection of Lonapegsomatropin once-weekly for 52 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAE Leading to Study DiscontinuationTime frame: Up to 52 Weeks

Locations

85 sites in 21 countries. Site status is shown where the registry gives one.

  • Ascendis Pharma Investigational Site

    Phoenix, Arizona

  • Ascendis Pharma Investigational Site

    Torrance, California

  • Ascendis Pharma Investigational Site

    Chicago, Illinois

  • Ascendis Pharma Investigational Site

    Indianapolis, Indiana

  • Ascendis Pharma Investigational Site

    Boston, Massachusetts

  • Ascendis Pharma Investigational Site

    Dearborn, Michigan

  • Ascendis Pharma Investigational Site

    Rochester, Minnesota

  • Ascendis Pharma Investigational Site

    St Louis, Missouri

  • Ascendis Pharma Investigational Site

    Las Vegas, Nevada

  • Ascendis Pharma Investigational Site

    Reno, Nevada

  • Ascendis Pharma Investigational Site

    New York, New York

  • Ascendis Pharma Investigational Site

    Portland, Oregon

  • Ascendis Pharma Investigational Site

    Dallas, Texas

  • Ascendis Pharma Investigational Site

    San Antonio, Texas

  • Ascendis Pharma Investigational Site

    Seattle, Washington

  • Ascendis Pharma Investigational Site

    Yerevan, Armenia

  • Ascendis Pharma Investigational Site

    Saint Leonards, New South Wales, Australia

  • Ascendis Pharma Investigational Site

    Sydney, New South Wales, Australia

  • Ascendis Pharma Investigational Site

    Box Hill, Victoria, Australia

  • Ascendis Pharma Investigational Site

    Fitzroy, Victoria, Australia

  • Ascendis Pharma Investigational Site

    Parkville, Victoria, Australia

  • Ascendis Pharma Investigational Site

    Perth, Western Australia, Australia

  • Ascendis Pharma Investigational Site

    Halifax, Nova Scotia, Canada

  • Ascendis Pharma Investigational Site

    Lyon, France

  • Ascendis Pharma Investigational Site

    Marseille, France

  • Ascendis Pharma Investigational Site

    Nantes, France

  • Ascendis Pharma Investigational Site

    Tbilisi, Georgia

  • Ascendis Pharma Investigational Site

    Tbilisi, Georgia

  • Ascendis Pharma Investigational Site

    München, Germany

  • Ascendis Pharma Investigational Site

    Athens, Greece

  • Ascendis Pharma Investigational Site

    Thessaloniki, Greece

  • Ascendis Pharma Investigational Site

    Haifa, Israel

  • Ascendis Pharma Investigational Site

    Petah Tikva, Israel

  • Ascendis Pharma Investigational Site

    Tel Aviv, Israel

  • Ascendis Pharma Investigational Site

    Genova, Italy

  • Ascendis Pharma Investigational Site

    Rome, Italy

  • Ascendis Pharma Investigational Site

    Rome, Italy

  • Ascendis Pharma Investigational Site

    Chiba, Japan

  • Ascendis Pharma Investigational Site

    Fukuoka, Japan

  • Ascendis Pharma Investigational Site

    Ishikawa, Japan

Showing 40 of 85 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.